Literature DB >> 21126756

Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?

Marisa A Vineyard1, Molly S Daniels, Diana L Urbauer, Michael T Deavers, Charlotte C Sun, Eric Boerwinkle, Diane C Bodurka, David M Gershenson, Jessica Crawford, Karen H Lu.   

Abstract

OBJECTIVE: To determine whether women with low-grade serous ovarian cancer (LGSOC) have personal and family histories of breast and ovarian cancer that are less suggestive of Hereditary Breast and Ovarian Cancer (HBOC), as compared to women with high-grade serous ovarian cancer (HGSOC).
METHODS: A single institution, case-control retrospective review of medical records was conducted. Personal demographics, personal cancer history, and family history of breast and ovarian cancer of women with LGSOC were collected and compared to controls with HGSOC, which is known to be associated with HBOC.
RESULTS: 195 cases of LGSOC and 386 controls with HGSOC were included in the analysis. Women with LGSOC were significantly less likely to have a first- or second-degree relative with breast or ovarian cancer (p=0.0016). Additionally, when the personal and family histories were quantified using the AMyriad BRC mutation prevalence tables, women with LGSOC had lower scores indicative of a less suggestive family history for HBOC (p=0.027).
CONCLUSIONS: In this study, women with LGSOC had family histories that were less suggestive of HBOC compared to women with HGSOC, especially when the degree of relatedness of affected relatives was taken into account. By beginning to determine if LGSOC is part of the tumor spectrum seen in HBOC, this study is an important step towards refining hereditary cancer risk assessment for women with ovarian cancer.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21126756     DOI: 10.1016/j.ygyno.2010.10.033

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study.

Authors:  Molly S Daniels; Sheri A Babb; Robin H King; Diana L Urbauer; Brittany A L Batte; Amanda C Brandt; Christopher I Amos; Adam H Buchanan; David G Mutch; Karen H Lu
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 2.  Genetic risk and gynecologic cancers.

Authors:  Laura L Holman; Karen H Lu
Journal:  Hematol Oncol Clin North Am       Date:  2012-02       Impact factor: 3.722

3.  MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma.

Authors:  Beryl Manning-Geist; Sushmita Gordhandas; M Herman Chui; Rachel N Grisham; Ying L Liu; Qin Zhou; Alexia Iasonos; Arnaud Da Cruz Paula; Diana Mandelker; Kara Long Roche; Oliver Zivanovic; Anna Maio; Yelena Kemel; Dennis S Chi; Roisin E O'Cearbhaill; Carol Aghajanian; Britta Weigelt
Journal:  Clin Cancer Res       Date:  2022-10-14       Impact factor: 13.801

Review 4.  Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research.

Authors:  Angiolo Gadducci; Stefania Cosio
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 5.  Low-Grade Serous Carcinoma of the Ovary: The Current Status.

Authors:  Abdulaziz Babaier; Hanan Mal; Waleed Alselwi; Prafull Ghatage
Journal:  Diagnostics (Basel)       Date:  2022-02-10

6.  Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.

Authors:  Antonella Turchiano; Daria Carmela Loconte; Rosalba De Nola; Francesca Arezzo; Giulia Chiarello; Antonino Pantaleo; Matteo Iacoviello; Rosanna Bagnulo; Annunziata De Luisi; Sonia Perrelli; Stefania Martino; Carlotta Ranieri; Antonella Garganese; Alessandro Stella; Cinzia Forleo; Vera Loizzi; Marco Marinaccio; Ettore Cicinelli; Gennaro Cormio; Nicoletta Resta
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.